The FDA has approved capivasertib (Truqap™, AstraZeneca Pharmaceuticals) in combination with fulvestrant for adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer. This indication is for patients with one or more PIK3CA/AKT1/PTEN alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 mo...

A phase 3 clinical trial (NCT00075764) reports that for postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer, adding fulvestrant (Faslodex®, AstraZeneca) to anastrozole (Arimidex®, AstraZeneca) as first-line therapy increases long-term survival in comparison with anastrozole alone. Approximately two thirds of breast cancers are HR-positive, meaning that the cancer cells have receptors that attach to the hormones estrogen and/or progesterone. For HR-positive cancer...

​The FDA has now expanded the indication for palbociclib (Ibrance®, Pfizer Inc.) in combination with an aromatase inhibitor or fulvestrant (Faslodex®, AstraZeneca) to include men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Because breast cancer in men is rare, comprising less than 1% of all breast cancer cases, men with breast cancer are more likely to be diagnosed at an older age and with a more advanced sta...